New Reports Examine Psychiatric Risks of Varenicline for Smoking Cessation
Available from: Henri-Jean Aubin
[Show abstract] [Hide abstract]
ABSTRACT: Strategies for assisting smoking cessation include behavioural counselling to enhance motivation and to support attempts to quit and pharmacological intervention to reduce nicotine reinforcement and withdrawal from nicotine. Three drugs are currently used as first-line pharmacotherapy for smoking cessation: nicotine replacement therapy, bupropion, and varenicline. Compared to placebo, the drug effect varies from 2.27 (95% CI 2.02-2.55) for varenicline, to 1.69 (95% CI 1.53-1.85) for bupropion, and to 1.60 (95% CI 1.53-1.68) for any form of nicotine replacement therapy. Despite some controversy regarding the safety of bupropion and varenicline, regulatory agencies consider these drugs as having a favourable benefit/risk profile. However, given the high rate of psychiatric comorbidity in dependent smokers, practitioners should closely monitor patients for neuropsychiatric symptoms. Second-line pharmacotherapies include nortriptyline and clonidine. This review also offers an overview of pipeline developments and issues related to smoking cessation in special populations: persons with psychiatric comorbidity and pregnant and adolescent smokers.
British Journal of Clinical Pharmacology 03/2013; 77(2). DOI:10.1111/bcp.12116 · 3.88 Impact Factor
Medicina Clínica 05/2013; · 1.42 Impact Factor
Medicina Clínica 02/2014; 142(4):180–181. DOI:10.1016/j.medcli.2013.03.008 · 1.42 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.